Clinical trials: Medicine
Rheumatoid Arthritis
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
This open-label study will evaluate the efficacy and safety of tocilizumab as monotherapy or in combination with methotrexate or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in participants with active…
- Trial name
- ACT-MOVE (NCT02046603)
- Testing
- Tocilizumab, DMARDs, Oral Corticosteroids
- Where
- 38 sites in United Kingdom
- Volunteers
- 162 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants
The purpose of this study is to characterize the effect of itraconazole (Part 1) and rifampin (Part 2) on the single-dose pharmacokinetics (PK) of TAK-788 and its active metabolites (AP32960 and AP32914) in healthy adult…
- Trial name
- NCT03928327
- Testing
- TAK-788, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Cancer, Gastric (Cardia, Body) Cancer
Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form.
- Conditions
- Solid Cancer, Gastric (Cardia, Body) Cancer, Esophageal Cancer, Colorectal Cancer (CRC)
- Trial name
- ESCAPE (NCT07114627)
- Testing
- Blood sampling for pharmacokinetics
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- Erasmus Medical Center
Pain
A Study of Whether 3 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication
To determine whether three new oral formulations of a strong pain killer release the drug into the body in a similar pattern as the already marketed reference capsule formulation with or without food
- Trial name
- NCT02446561
- Testing
- MRXXX, MR1XXX, MR2XXX
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Mundipharma Research Limited
Obesity & Overweight, Type 2 Diabetes
Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy
This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy.
- Conditions
- Obesity & Overweight, Type 2 Diabetes, Type 2 Diabetes (Adult Onset), Obesity Type 2 Diabetes Mellitus
- Trial name
- NCT07641361
- Testing
- Hydration Plus, Control
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- State University of New York at Buffalo
Epilepsy
Effects of Transcranial Direct Current Stimulation (TDCS) in Drug-resistant Partial Epilepsy
Drug-resistant partial epilepsy has a heavy impact on quality of life and sometimes on life expectancy itself. Only a minority of patients may benefit from a curative epilepsy surgery.
- Trial name
- BRAINSTIM (NCT02465970)
- Testing
- STARSTIM
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Rennes University Hospital
Opioid Overdose, Substance Use Disorders
Quantitative Xylazine Measurement in ED
Quantitative Xylazine Measurement Among Non-Fatal Opioid Overdose (OD) Patients in the Emergency Department (ED)
- Trial name
- NCT06949605
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Obesity, Diabetes
Penn Medicine Food Market Study
The goal of this interventional study is to test ways to improve the effectiveness of a healthy foods prescription program in increasing the purchase of healthy foods for patients who have both obesity (BMI >or= 30) and diabetes…
- Trial name
- NCT06283394
- Testing
- Storefront Choice Architecture, Fresh Funds, Loss Framing
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- University of Pennsylvania
Advanced Biliary Tract Cancer(BTC)
Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer
This is a single-arm, Phase II, multicenter clinical trial evaluating sacituzumab tirumotecan in patients with TROP2-positive advanced biliary tract cancer who have experienced disease progression after, or intolerance to, at…
- Trial name
- NCT07701122
- Testing
- Sacituzumab Tirumotecan (SKB264)
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cancer, Cardiotoxicity
BIOMARKER and IMAGING CHARACTERISATION of INFLAMMATORY ATHEROMA in PATIENTS RECEIVING IMMUNOTHERAPY and ANGIOGENESIS INHIBITORS
The advent of immunotherapy (immune checkpoint inhibitors [ICI]) has been an extremely important advancement for cancer treatment in recent decades.
- Conditions
- Cancer, Cardiotoxicity, Atherosclerotic Disease
- Trial name
- BIOCAPRI (NCT06597045)
- Testing
- PET/CT with 18-FDG
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- NHS Greater Glasgow and Clyde
Breast Neoplasms, Neoplasm Metastasis
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
This study is a prospective, multicenter, phase II randomized clinical trial. It is planned to enroll 60 patients with advanced HER2 negative breast cancer, who will be randomly assigned to the experimental group and the control…
- Conditions
- Breast Neoplasms, Neoplasm Metastasis, Drug Therapy, Bevacizumab
- Trial name
- NCT06539559
- Testing
- Eribulin, Bevacizumab
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Wang Jiayu
Primary Care Quality Metrics, Well Child Visits in First 15 Months of Life NQF 1392
The Impact of Patient Complexity on Healthcare Utilization
Healthcare providers are routinely being assessed for metrics designed to assess the quality of the care they deliver. There is growing consensus that these measurements, which typically assess the percentage of patients meeting…
- Conditions
- Primary Care Quality Metrics, Well Child Visits in First 15 Months of Life NQF 1392, Diabetes Mellitus NQF 0059, Colorectal Cancer Screening NQF 0034
- Trial name
- NCT03327896
- Testing
- Charlson score and Community Social Deprivation
- Volunteers
- 200,000 people
- Sponsor
- OCHIN, Inc.
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
Cardiac Arrest With Successful Resuscitation, Hypothermia
Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest
Mild hypothermia improves neurological outcome after cardiac arrest. Neuromuscular blockers are in use, together with analgesia and sedation, during the cooling process in many centers to prevent shivering.
- Conditions
- Cardiac Arrest With Successful Resuscitation, Hypothermia, Skeletal Muscle Relaxant Overdose
- Trial name
- RELAX (NCT01719770)
- Testing
- rocuronium
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
HIV Infections, Obesity
Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain
The purpose of this research study is to understand why certain HIV medication regimens (called anti-retroviral or ARV medications) cause more weight gain than others.
- Trial name
- NCT05463783
- Testing
- Biktarvy, Symtuza
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- East Carolina University
Critical Limb Ischemia
A Safety and Tolerability Study of RJX Drug Product in Healthy Participants
Designed as a single center, two-part, double-blind, placebo-controlled, randomized study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RJX in healthy participants.
- Trial name
- NCT03680105
- Testing
- RJX
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Reven Pharmaceuticals, Inc.
Prostate Cancer, Prostatic Intraepithelial Neoplasia
Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.
Pre-surgical, window-of-opportunity trials provide a suitable model to assess the activity of preventive interventions in a cost-effective manner using tissue biomarkers as surrogate endpoints.
- Trial name
- 2F (NCT06601205)
- Testing
- Flutamide, Finasteride
- Where
- Italy
- Volunteers
- 125 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
Bipolar I Disorder
PK Effects of Bifeprunox & Valproate in Bipolar I
The study is to evaluate the effect of bifeprunox on the pharmacokinetics of valproate in subjects with Bipolar I Disorder after multiple dose administration.
- Trial name
- NCT00141505
- Testing
- Bifeprunox
- Where
- United States
- Sponsor
- Solvay Pharmaceuticals
Post-Concussion Symptoms, Distorted; Balance
Comparing the Effect of Osteopathic Manipulative Medicine (OMM) Versus Counseling in the Treatment of Concussion
Concussion or mild traumatic brain injury (TBI) is a challenging injury for physicians to manage and is among the most serious disabling neurological disorders.
- Trial name
- NCT02750566
- Testing
- Osteopathic Manipulative Treatment, Counseling
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- New York Institute of Technology
Epilepsy, Bone Loss
Antiepileptic Drugs and Osteoporotic Prevention Trial
Study Design: (e.g., Controlled, Double-Blind, Randomized, Parallel): Randomized, double-blind, placebo controlled of a bisphosphonate in the prevention of bone loss associated with the use of antiepileptic drugs.
- Conditions
- Epilepsy, Bone Loss, Osteoporosis, Fractures
- Trial name
- ADOPT (NCT00869622)
- Testing
- Risedronate
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Boston VA Research Institute, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.